X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sterling Biotech with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs TEVA PHARMA (Israel) - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STERLING BIOTECH   TEVA PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
TEVA PHARMA
Dec-13
STERLING BIOTECH/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs112,831-   
Low Rs32,459-   
Sales per share (Unadj.) Rs26.81,624.6-  
Earnings per share (Unadj.) Rs-15.0101.5-  
Cash flow per share (Unadj.) Rs-5.5232.8-  
Dividends per share (Unadj.) Rs088.84-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs54.91,804.7-  
Shares outstanding (eoy) m267.87848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.6 15.9%   
Avg P/E ratio x-0.526.1 -1.8%  
P/CF ratio (eoy) x-1.311.4 -11.2%  
Price / Book Value ratio x0.11.5 8.6%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,8622,242,943 0.1%   
No. of employees `0001.444.9 3.0%   
Total wages/salary Rs m5470-   
Avg. sales/employee Rs Th5,303.330,652.9 17.3%   
Avg. wages/employee Rs Th403.80-   
Avg. net profit/employee Rs Th-2,959.01,914.9 -154.5%   
INCOME DATA
Net Sales Rs m7,1811,377,695 0.5%  
Other income Rs m430-   
Total revenues Rs m7,2231,377,695 0.5%   
Gross profit Rs m947377,283 0.3%  
Depreciation Rs m2,543111,360 2.3%   
Interest Rs m4,37727,060 16.2%   
Profit before tax Rs m-5,931238,862 -2.5%   
Minority Interest Rs m01,085 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-156,800 0.0%   
Tax Rs m-1,924-2,916 66.0%   
Profit after tax Rs m-4,00786,064 -4.7%  
Gross profit margin %13.227.4 48.2%  
Effective tax rate %32.4-1.2 -2,657.5%   
Net profit margin %-55.86.2 -893.2%  
BALANCE SHEET DATA
Current assets Rs m14,335930,490 1.5%   
Current liabilities Rs m49,809811,466 6.1%   
Net working cap to sales %-494.08.6 -5,718.3%  
Current ratio x0.31.1 25.1%  
Inventory Days Days40391 444.3%  
Debtors Days Days17196 177.9%  
Net fixed assets Rs m55,432449,986 12.3%   
Share capital Rs m2683,391 7.9%   
"Free" reserves Rs m13,9350-   
Net worth Rs m14,7011,530,358 1.0%   
Long term debt Rs m9,478704,446 1.3%   
Total assets Rs m73,9883,148,476 2.3%  
Interest coverage x-0.49.8 -3.6%   
Debt to equity ratio x0.60.5 140.1%  
Sales to assets ratio x0.10.4 22.2%   
Return on assets %0.53.6 13.9%  
Return on equity %-27.35.6 -484.6%  
Return on capital %-6.44.9 -130.3%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Net fx Rs m1,8350-   
CASH FLOW
From Operations Rs m1,719219,533 0.8%  
From Investments Rs m-3,148-77,790 4.0%  
From Financial Activity Rs m1,426-263,345 -0.5%  
Net Cashflow Rs m-3-121,601 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 67.82 Rs / USD

Compare STERLING BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare STERLING BIOTECH With: WOCKHARDT LTD.  DR. REDDYS LAB  PIRAMAL ENTERPRISES  TORRENT PHARMA  ALKEM LABORATORIES  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views On News

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Jun 18, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS